
Coronavirus antiviral drug shows promise in hamsters, enters human testing
Fox News
An experimental antiviral treatment against the virus causing COVID-19 showed promise in animal studies and has entered human clinical trials, according to the National Institutes of Health (NIH).
"We show that MK-4482, when administered either starting at 12 h prior to SARS-CoV-2 infection, or even 12 h post-infection, significantly decreases viral lung loads and pathology, but does not affect shedding from the upper respiratory tract," the study reads. "These findings support the potential of MK-4482 as an orally administered drug for high-risk exposure and possibly therapeutic use in humans." The study involved three groups of hamsters; a "pre-infection treatment group; a post-infection treatment group" and a control group. For the treatment groups, scientists gave the drug every 12 hours for three days. By the end, the treated animals in both groups revealed "significantly fewer lesions in the lungs" and a 100-fold drop in infectious virus in the lungs compared to the untreated control group.More Related News